Skip to main content
. 2022 Jul 16;17(4):441–451. doi: 10.1007/s11523-022-00899-6

Fig. 2.

Fig. 2

Progression of patients until mCRPC in the European Cancer Prostate Registry–Median [Q1Q3] in years. mCRPC metastatic castration-resistant prostate cancer, mHSPC metastatic hormone-sensitive prostate cancer, nmCRPC non-metastatic castration-resistant prostate cancer, PrCa prostate cancer